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We hypothesized that somatostatin-14 (88-14) might 
inhibit insulin-stimulated hepatic growth. Rat hepato- 
cytes were isolated by a two-step collagenase perfusion 
technique and cultured on Matrigel. Differentiated he- 
patocyte function was documented by albumin synthe- 
sis. Hepatocytes were incubated with insulin in thepres- 
ence or absence of SS- 14. Hepatocyte proliferation was 
assessed by tritiated thymidine ([SH]thy) incorporation 
into DNA. [SH]thy incorporation was increased by 
230% in the presence of insulin and was essentially 
abolished by the addition of 88-14. Insulin-stimulated 
cyclic-AMP accumulation was also decreased from 190 
to 108% of control levels (P < 0.05) by the addition of 
88-14. Pretreatment with pertussis toxin, which inac- 
tivates the inhibitory G-protein, Gi, blocked the effect 
of 88-14. Conclusions: (i) In the rat, SS-14 effectively 
blocks insulin-stimulated [‘HIthy incorporation into 
DNA, possibly by blocking intracellular CAMP accu- 
mulation. (ii) Pertussis toxin blocks the growth inhibi- 
tory effects of SS-14, suggesting that inhibitory G pro- 
teins are involved in the mechanism of SS-14 action. 
Somatostatin may be useful in studying the role of sec- 
ond messengers in cell growth. o 1991 Academic P-S, IN. 
INTRODUCTION 
Most of our knowledge about growth control in hepa- 
tocyte cell culture has been derived from observing the 
action of growth stimulants such as insulin, epidermal 
growth factor, and glucagon [ 11. The proliferative state 
is affected by the complex interactions of growth factors, 
ion flux, nutrient state, and growth inhibitors. In the 
case of hepatocytes, the inability to identify inhibitors 
and difficulties in distinguishing growth inhibition from 
cytotoxicity in cell culture have hampered the study of 
inhibitory growth regulation. Despite these difficulties, 
several compounds have been shown to inhibit hepato- 
cyte growth, including transforming growth factor p 
(TGFP), arginase, and adrenal steroids [2]. 
1 This work was supported by NIH Grant 1 R29 DK42485-01 (SER) 
and a Career Development Award from the Society for Surgery of the 
Alimentary Tract (SER). 
Somatostatin (SS-14) has been shown to inhibitprolif- 
eration of a number of normal and neoplastic cell types 
in culture. Somatostatin has been shown to inhibit 
growth of pancreatic acinar cells, rat thyroid follicular 
cells, and lymphocytes [3-51. Somatostatin-14 and sev- 
eral analogs have also been shown to inhibit growth of 
cultured pancreatic tumor cells and can also inhibit pro- 
liferation of several breast cancer cell lines [6, 71. Al- 
though no work has been published looking at the effect 
of SS-14 on hepatocyte growth, it has been reported to 
inhibit rat liver regeneration in uiuo [8]. Recently, SS-14 
has been shown to inhibit insulin-stimulated but not 
triiodothyronine-stimulated growth of the well-differ- 
entiated human hepatoma (Hep3B) cell line [9]. 
Although no direct effects of SS-14 on hepatocyte 
growth have been previously reported, SS-14 appears to 
influence a number of hepatic functions. Several authors 
have documented a reduction in bile acid-independent 
canalicular bile flow in response to SS-14 in the intact 
rat as well as in an isolated, perfused rat liver [lo]. In 
humans, continuous intravenous infusion of SS-14 de- 
creases output of bile, bile acid, cholesterol, andphospho- 
lipid [ll]. Evidence from several laboratories has re- 
cently shown that SS-14 may regulate liver function by 
blocking the effects of the intracellular second messen- 
ger, cyclic AMP [12, 131. 
Based on evidence that somatostatin inhibits insulin- 
stimulated Hep3B growth in vitro and also inhibits he- 
patic function and regeneration in uivo, we hypothesized 
that SS-14 might inhibit insulin-induced hepatocyte pro- 
liferation in culture and that this model might be a use- 
ful tool for studying the mechanism(s) responsible for 
hepatocyte proliferation. 
MATERIALS AND METHODS 
Chemicals. Collagenase (type I), media, N-2-hy- 
droxyethylpiperazine-N’-2-ethanesulfonic acid (Hepes), 
Hanks’ buffer, and rat serum albumin were purchased 
from Sigma (St. Louis, MO). Somatostatin-14 and insu- 
lin were obtained from Peninsula Laboratories (Bel- 
mont, CA). Matrigel and Dispase were obtained from 
Collaborative Research (Bedford, MA). Anti-rat albu- 
min was obtained from Organon (Organon Teknika 
0022-4804/91$1.50 
Copyright 0 1991 by Academic Press, Inc. 
All rights of reproduction in any form reserved. 
386 
RAPER ET AL.: ANTI-HEPATOTROPHIC EFFECTS OF SOMATOSTATIN 387 
Corp, PA). All reagents used for polyacrylamide gel elec- 
trophoresis and immunoblot analysis were electrophore- 
sis grade and were obtained from Bio-Rad (Richmond, 
CA) or Boeringer-Mannheim (Indianapolis, IN). [35S] - 
Cysteine was obtained from Amersham (Arlington 
Heights, IL). 
Hepatocyte isolation. Primary cultures of rat hepato- 
cytes were isolated by the method of Gumucio [14]. 
Briefly, rat liver was portally perfused first with M$+/ 
Ca2+-free Hanks’ buffer at 37°C and then with Eagle’s 
minimal essential medium (EMEM) containing 0.05% 
collagenase (type I, Sigma). The liver was excised and 
placed in a petri dish containing fresh EMEM with 
0.05% collagenase. Glisson’s capsule was stripped and 
cells were released by gentle manipulation. The result- 
ing crude preparation was filtered through 250~Frn and 
100-pm nylon mesh. Collagenase was inactivated with 
0.5 ml fetal calf serum. Viability was in excess of 90% as 
assessed by trypan blue exclusion. 
[3H]Thymidine incorporation assay. [3H]Thymidine 
incorporation into DNA was used as a marker for hepa- 
tocyte proliferation. Freshly isolated hepatocytes were 
plated at a density of lo5 per 16-mm tissue culture dish 
coated with 250 ~1 Matrigel, (laminin, heparan sulfate, 
type IV collagen) per well [ 151. After a 24-hr attachment 
period in EMEM, fresh media including the various pep- 
tides was added. After six hr, [3H]thy (2 &i/well) was 
added and the incubation was allowed to proceed over- 
night. Cells were removed from the Matrigel with Dis- 
pase, a neutral protease produced by Bacillus polymyxa. 
Half of the cell suspension was used for quantitation of 
incorporation of [3H]thy; the rest was used to measure 
DNA content. Cells for t3H]thy measurement were 
placed on GF/C Whatman filters, rinsed twice with 1 ml 
of ice-cold 15% trichloroacetic acid, and then rinsed 
once with 70% EtOH. Filters were dried, placed in 10 ml 
of Ecolume scintillation cocktail, and counted in a Beck- 
man LS 6000LL scintillation counter. DNA content was 
measured with the diphenylamine reaction for desoxy- 
pentose. 
Cyclic AMP assay. Freshly isolated hepatocytes 
(105/tube) were incubated with the appropriate reagents 
for 5 min. At the end of the incubation period, test tubes 
were placed in a 4°C ice bath for 10 min, vortexed, and 
centrifuged at 18OOg for 10 min at 4°C. The pellet was 
precipitated with 15% TCA, ether extracted, and lyophi- 
lized. Cyclic AMP levels were measured by competitive 
protein binding assay using the Amersham kit (Arling- 
ton Heights, IL). 
SDS-PAGE analysis. Media or protein standards 
were solubilized in sample buffer (0.0625 M Tris-HCl 
(pH 6.8), 2.3% SDS (w/v), 10% glycerol (w/v), 5% ,& 
mercaptoethanol (v:v), 5% Bromphenol blue) by heating 
at 100°C for 3 min. Samples were subjected to electro- 
phoresis in 7.5% acrylamide with 1% SDS after the 
method of Savion [16]. Some of the electrophoresed gels 
were fixed, stained with the Bio-Rad silver stain kit, and 
dried. Others were transferred to nitrocellulose mem- 
branes for immunoblot analysis. 
Immunoblot analysis. Immunoblotting was per- 
formed after the method of Blake et al. [17]. Briefly, 
proteins from PAGE gels were transferred to nitrocellu- 
lose using electrophoretic transfer. After blocking with 
20 mM Tris-buffered saline (pH 7.5,25”C, 60 min) and 
3% gelatin, the primary rabbit anti-rat albumin anti- 
body was added at dilutions from 1:lOO to l:lOOO, with 
1:500 giving the best results. A goat anti-rabbit IgG con- 
jugated to alkaline phosphatase was used as the second 
antibody. 
Statistical analysis. All analysis was done on a Mac- 
intosh II microcomputer with Statview II statistical 
analysis software. Analysis of variance (ANOVA) or 
Student’s t test was done for sample means, and Wil- 
coxon’s signed rank test was done to compare mean per- 
centages. 
RESULTS 
Viability and maintenance of differentiated h,epatocyte 
function in culture. To rule out the possibility of cell 
loss as a cause for differences in subsequent experi- 
ments, hepatocytes (1 X 105) were incubated for 24 hr in 
the presence of EMEM, insulin (20 nM), somatostatin- 
14 (10 nM), or both. On observation under the inverted 
microscope, cells were uniform in size and shape. Cells 
were removed from the tissue culture plates by Dispase 
treatment and cell number was analyzed by both hemo- 
cytometer and Coulter counter. No significant differ- 
ences in cell number, shape, or percentage viability were 
seen after 24 hr of treatment. 
Albumin synthesis was used as a marker for differen- 
tiated hepatocyte function. Hepatocytes were incubated 
in EMEM in the presence or absence of insulin and/or 
somatostatin-14. [35S]Cysteine (1 &i) was added to the 
cultures. Media was aspirated at 24 and 48 hr and ana- 
lyzed by both immunoprecipitation and immunoblot 
techniques. Figure 1 shows the maintenance of incorpo- 
ration of [35S]cysteine into immunologically recogniz- 
able albumin, with an efficiency of incorporation of 
about 10% of the original dose of [35S]cysteine. Figure 2 
represents an immunoblot of media obtained from hepa- 
tocyte cultures after 24 hr, again revealing the presence 
of albumin. 
The effect of somatostatin-14 on basal and insulin- 
stimulated [3H]thymidine incorporation. The addition 
of insulin significantly increased the incorporation of 
[3H]thymidine into DNA in hepatocyte culture and this 
effect could be completely abolished by the addition of 
somatostatin-14 in a dose-dependent manner (Fig. 3). 
Autoradiographic study of the nuclear labeling index of 
cells exposed to EMEM with or without insulin or insu- 
lin and somatostatin-14 revealed a 245% increase in la- 
388 JOURNAL OF SURGICAL RESEARCH: VOL. 50, NO. 4, APRIL 1991 
60 
EMEM Insulin ss-14 Ins + ss-14 
L 
Hepatocytes consistently synthesized albumin as mea- 
sured by the incorporation of [%]cysteine into protein immunopreci- 
pitable by an anti-rat albumin antibody. The data are expressed as a 
percentage of EMEM-treated hepatocytes. Shaded bars indicate a 24- 
hr incubation; open bars indicate a 48-hr incubation. The data repre- 
sent one of four experiments. 
beled nuclei with insulin which could be reversed by the 
addition of somatostatin-14 (Fig. 4). 
The effect of insulin and somatostatin-14 on cyclic 
AMP accumulation in hepatocyte culture. A small but 
reproducible increase in CAMP levels over that seen in 
cells grown in EMEM alone was detected in hepatocytes 
stimulated by insulin. This rise in CAMP could be coun- 
teracted by the addition of somatostatin-14 (Fig. 5). 
The effect of pertussis toxin on somatostatin inhibition 
of thymidine incorporation and CAMP accumulation. 
Pertussis toxin (50 ng) was added to hepatocyte cultures 
prior to the addition of insulin (20 nM) or somatostatin- 
14 (10 nM). Pertussis toxin was able to reverse the 
growth inhibitory effects of somatostatin-14 on thymi- 
dine incorporation (Fig. 6). 
DISCUSSION 
In this study, we have shown that somatostatin-14 
inhibits insulin-stimulated DNA synthesis in a dose-de- 
pendent manner (Fig. 3). This effect did not result from 
FIG. 2. Immunoblot of media from rat hepatocytes incubated on 
Matrigel. Note the presence of a protein band that stains positive for 
the rabbit anti-rat albumin antibody in the presence of insulin or so- 
matostatin. The data are representative of three experiments. (SS-14, 
somatostatin-14). 
EMEM lnsulln 0.1 1.0 10.0 
- Ins + SS-14 (nM) - 
FIG. 3. Inhibition of insulin-stimulated thymidine incorporation 
by somatostatin-14. Hepatocytes (lOs/well) were incubated with or 
without insulin (Ins, 20 n&f) and increasing doses of somatostatin-14 
(SS-14). The data are representative of six experiments (*P < 0.05). 
a toxic injury at the doses used, since the cells appeared 
viable, cell numbers were similar, and albumin synthesis 
was not adversely affected. To avoid the possible growth 
effects of uncharacterized serum components that might 
affect growth regulation, cells were allowed to grow in 
media for 24 hr before any growth studies were per- 
formed [ 181. This allowed us to carefully analyze the 
effects of insulin and somatostatin-14 on thymidine in- 
corporation and CAMP content. Inhibition of hepatic 
regeneration by somatostatin has previously been re- 
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FIG. 4. Labeling index of hepatocytes treated with insulin (Ins, 
20 nM) and somatostatin-14 (SS-14,10 n&f). The labeling index was 
calculated as the number of nuclei containing autoradiographic grains 
divided by the total number of counted nuclei. The data represent 
photographs of six wells for each treatment and an average of 150 
nuclei in each well. Insulin-treated hepatocytes had a significantly 
higher labeling index when compared to the other treatment groups (P 
< 0.05). 
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impossible to determine whether or not somatostatin 
was exerting a direct or indirect effect on the liver rem- 
nant [8]. 
The ability of somatostatin to inhibit hepatocyte 
growth is consistent with its anti-proliferative effects on 
other cultured cell lines such as mouse splenocytes and 
human blood T-lymphocytes [19,20]. Somatostatin has 
also been shown to inhibit proliferation of FRTL5 rat 
follicular thyroid cells [5]. Somatostatin can also inhibit 
certain tumors in several in vivo and in vitro model sys- 
tems and has lead to speculation that it may be poten- 
tially useful in the treatment of certain neoplasms. 
Somatostatin appears to inhibit cell growth by both 
cyclic AMP-dependent and -independent mechanisms. 
Somatostatin has been shown to inhibit hepatocyte pro- 
liferation induced by isobutyl methyl-xanthine and di- 
butyryl cyclic AMP, both of which act via cyclic AMP- 
dependent mechanisms [21]. Our data show that pre- 
treatment of hepatocytes by pertussis toxin, which 
increases adenyl cyclase activity by inactivating an in- 
hibitory G protein, blocks the inhibitory effect of so- 
matostatin (Fig. 6). Although somatostatin is generally 
thought to act partly by decreasing cellular CAMP levels, 
non-CAMP-dependent effects have recently been de- 
scribed [22]. Inhibition of insulin-like growth factor-I- 
stimulated FRTL5 cell growth by somatostatin has been 
demonstrated and appears to be independent of CAMP 
pathways [5]. 
The effect of insulin on hepatic cyclic AMP levels has 
been studied by several investigators. Jefferson et al. 
were unable to document stimulation of hepatic CAMP 
by insulin [23]. Loten et al. showed that insulin activated 
a low Km hepatic phosphodiesterase which could de- 
crease hepatic CAMP [24]. These studies, however, were 
performed at 10 to 30 min after incubation with insulin. 
EMEM lnsulln ss-14 1ns+ss-14 
FIG. 5. Effect of insulin (Ins) and somatostatin-14 (SS-14) on 
hepatic CAMP levels. Hepatocytes (1 X ld) were incubated for 5 min 
with insulin (20 n&f), SS-14 (10 nM), or both and then analyzed for 
CAMP. Insulin-treated hepatocytes had a significantly higher CAMP 
content when compared to the other treatment groups (P < 0.05). The 
data represent one of five experiments. 
TT 
-PT +PT 
FIG. 6. Effect of pertussis toxin (PT) on the anti-proliferative 
effect of somatostatin. Hepatocytes (105/well) were preincubated with 
pertussis toxin (50 ng) or media. The hatched bars indicate cells 
treated with insulin (20 nM). The open bars indicate cells treated with 
insulin (20 nM) and somatostatin-14 (10 nM). The data are represen- 
tative of three experiments. 
In the present study, we observed a small but reproduc- 
ible increase in hepatic CAMP levels at 5 min after insu- 
lin stimulation. This observation is consistent with the 
findings of Gettys et al., who used hepatocytes preloaded 
with a hydrolyzable CAMP analog and documented in- 
creased CAMP levels at 0.5-2.0 min followed by a 
plateau at 5 min and a decline to baseline by 7 min and 
beyond [25]. This early but transient increase in hepato- 
cyte CAMP after insulin treatment may provide the sig- 
nal for hepatocytes to initiate mitosis [26]. 
Insulin has been shown to antagonize the effects of 
glucagon on hepatic carbohydrate metabolism despite 
the synergistic actions of insulin and glucagon on hepa- 
tocyte proliferation. This argues against the possibility 
that alteration of cellular CAMP levels is the major mech- 
anism responsible for the hepatotrophic effects of insu- 
lin. More likely, insulin action and the inhibitory effects 
of somatostatin on insulin action are mediated through 
cyclic AMP-independent pathways such as protein 
phosphorylation or calcium influx. The synergistic ef- 
fects of insulin, glucagon, and epidermal growth factor 
on hepatocyte growth suggest that each may act through 
different mechanisms [ 271. 
In summary, somatostatin exerts an anti-proliferative 
effect on insulin-stimulated hepatocytes in vitro. The 
ability to identify growth inhibitory factors using an in 
vitro hepatocyte model will hopefully facilitate further 
studies of the intracellular mechanisms responsible for 
control of hepatic regeneration. 
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